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• We conducted a review comprising of two components 
– First, we identified single technology appraisals (STAs) submitted to the NICE by searching the NICE 
website (www.nice.org.uk)
– Following this, we undertook a systematic search using Medline and EMBASE via Ovid to identify 
published economic evaluation of cancer treatments using a model
• Searches were performed in November 2018, capturing relevant publications and STAs published since 
2013 up to the date of searching
• Inclusion criteria are described in Table 1
Reporting of findings
• Identified studies were reviewed to establish the model structure used
• Model structures were categorised as one of the following:
– A PartSA model (shown conceptually in Figure 1)
– A Markov state-transition model (shown conceptually in Figure 2)
– Other 
• The author-reported reasons for the model structure used were also extracted and summarised




• The screening process is shown in Figure 3, the review identified 100 NICE STAs and 124 published 
studies relevant to the topic
Model structures used
• The model structures used within identified studies are reported in Table 2
• Published studies appeared to report a greater use of discrete-time state transition-models (n=102, 82%) 
when compared to NICE submissions
• Partitioned-survival analysis (n=54, 54%) and discrete-time state-transition structures (n=41, 41%) were the 
main structures submitted to NICE
Justification of model structures
• Justification of model structures and consideration of structural uncertainty were very limited within 
publications; a minority  of  published  studies  (22%) reported any strengths or limitations associated with 
the chosen model structure
• The NICE STAs typically included more discussion on model choice (a requirement of the submission 
template)
– Justification was most often based on case precedence and ability to incorporate data from the trial or 
literature directly
– The ERGs rarely commented on the merits of the companies’ submitted model structures. Criticisms 
raised by ERGs in relation to the model structure used by the company included the lack of calibration 
between  outcome  measures, an ‘over-simplification’ of the final health state, seemingly ‘counterintuitive’ 
results and structural assumptions that were considered ‘inappropriate’
Results
NICE, n (%) Published studies, n (%)
PartSA 54 (54%) 15 (12%)
Markov state-transition 41 (41%) 102 (82%)
Other 5 (5%) 7 (6%)
Total 100 124
Table 2. Model structures used in NICE submissions and published studies
Key: PartSA, partitioned survival analysis.
Conclusions
• There appears to be a stronger dominance of the partitioned-survival analysis approach in 
submissions to NICE, however, we believe many of the published state transition models have 
been incorrectly labelled and are partitioned-survival analysis
– There is a clear need to improve the reporting of modelling structures within the published 
literature, especially when considering recent developments in modelling methods which may 
introduce further complexity in describing model structures used
• Other structures, such as a decision tree or discrete-event simulation, have also been utilised in 
submissions and within the published literature but only in minority of cases
– This finding is perhaps unsurprising as a key finding of the review was that model structures 
were often justified by citing case precedence. However, it is our opinion that this should not be 
considered a sufficient basis to determine the preferred model structure
• The justification for a given model structure was very limited within the identified studies, despite a 
recognition in the literature that model structure can greatly influence cost-effectiveness results 
– The validity of the cost-effectiveness analyses presented in HTA submissions or published 
literature would be greatly improved if presented with a thorough rationale for the choice of 
model structure 
– In addition, with improved documentation of the choice concerning model structures, future 
research may be better informed as to the decisions made to inform previous analysis, and 
whether or not the stated rationale is still applicable
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• As demand for treatment grows and healthcare budgets remain finite, decision makers require the results of 
cost-effectiveness analysis to make informed decisions in relation to the reimbursement of new cancer 
treatments
– In the United Kingdom, cost-effectiveness analyses are routinely submitted to health technology 
assessment (HTA) agencies, such as the National Institute for Health and Care Excellence (NICE) in 
England and Wales, and the Scottish Medicines Consortium (SMC)
• As of May 2019, NICE have published 264 technology appraisals on cancer drugs, which have resulted 
in 327 individual recommendations on cancer drugs1
• Cancer drugs make up 45.8% of all published technology appraisals carried out by NICE, and 36.7% of 
all individual recommendations made1
• In company submissions of cost-effectiveness analyses for cancer treatments, a variety of different 
modelling approaches have been utilised to date
– In June 2017, the NICE Decisions Support Unit (DSU) published Technical Support Document 19, which 
presented a critical review of partitioned survival analysis (PartSA) for decision modelling in health care2
– The review found that of the 30 cancer appraisals considered, PartSA was used in 22 (73%) of the 
appraisals2
• Since publication of NICE DSU TSD 19, there have been many more submissions of cancer drugs to NICE, 
as well as other published cost-effectiveness analyses in peer-reviewed publications
– This study was conducted to summarise the key modelling approaches used to show cost-effectiveness 
in oncology, as well as their advantages and limitations
– We expanded on the scope of the review conducted to inform NICE DSU TSD 19 to include other 
published studies (i.e. not just NICE appraisals) to understand if there were any differences between 
analyses used to inform HTA submissions to NICE versus those published as research
• To identify which model structures are most frequently used to inform submissions to NICE and published 
cost-effectiveness studies
• To understand the reasons behind the selection of a given model structure, based on the rationale provided 
by the author(s)
Objectives
























Survival curves produced using 
statistical extrapolation methods 
(e.g. parametric survival models)
The proportion of patients residing in each health 
state at each model cycle is determined by reading the 
relevant proportions from the survival curves
Costs and effects are then prescribed 
to each health state, and summed over 
the model time horizon to establish 
cost-effectiveness results
Figure 2. Concept of the Markov state-transition model structure
Progression-free Progressed
Dead
Transition probabilities are calculated using 
statistical software. Plausible transitions are 
denoted by arrows (including the possibility of 
remaining in the same health state)
In a Markov state-transition model, the probability 
of leaving a given health state per unit time is 
assumed to be constant, and so the model exhibits 
the ‘memoryless’ property (i.e. future transitions 
are not directly related to past events)
Costs and effects are then prescribed to each 
health state, and summed over the model time 
horizon to establish cost-effectiveness results
Table 1. Inclusion criteria
Criterion Requirement for inclusion
Population People with cancer (no restriction on the type of cancer)
Intervention Pharmacological interventions aimed at treating cancer (increasing health and length of life). 
Interventional studies looking at complications of cancer (e.g. treating anaemia or infections), 
surgical interventions and precision medicine-focused studies were excluded
Comparator Comparison with any active intervention, usual care, best supportive care or palliative care
Methods Studies were required to report the development and use of a decision-analytic model. 
Multiple technology and highly specialised technology appraisals were excluded
Outcomes Full economic evaluations (cost-effectiveness or cost-utility studies)
Other Journal articles published in English language from 2013 up until November 2018. Full-text 
articles (excluding protocols, case reports, conference proceedings or discussion pieces) were 
included from the published literature. STAs were included if the necessary documents were 
available via the NICE website. Publications were excluded if they described the findings of a 
NICE technology appraisal, or were highlighted within the publication as a country adaptation 
of a pre-existing published model or NICE STA
Figure 3. PRISMA diagram
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